MOMENTUM 3 and UNOS registry propensity-matched comparison
Comparative analysis between HeartMate 3 Left Ventricular Assist Device (LVAD) and heart transplantation (HTx) in heart failure patients under 50, using data from the MOMENTUM 3 trial and the UNOS registry.
In advanced heart failure patients <50, 2-year outcomes showed:
From time of implant or transplantation, HeartMate 3 LVAD and HTx patients have similar survival of ~90%.
From time of implant or HTx listing, HeartMate 3 LVAD patients have a 13%* decreased risk of death compared to risk of death or delisting** for HTx candidates.
*Absolute risk difference: 90.1%-76.7%=13.4%
**Delisted for worsening health
MAT-2506017 v4.0